- Home
- NXL vs LGVN Comparison
NXL vs LGVN Comparison
Compare NXL & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXL | LGVN |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 17.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NXL | LGVN |
|---|---|---|
| Price | $1.08 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $6.50 |
| AVG Volume (30 Days) | 261.4K | ★ 422.9K |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $156,931.00 | ★ $1,437,000.00 |
| Revenue This Year | $38.28 | N/A |
| Revenue Next Year | $185.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.70 | $0.59 |
| 52 Week High | $4.49 | $2.24 |
Technical Indicators
Market Signals| Indicator | NXL | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 40.02 |
| Support Level | $0.93 | $0.60 |
| Resistance Level | $1.12 | $0.67 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 35.20 | 32.17 |
Price Performance
Historical ComparisonAbout NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.